XIROMED supplier risk profile Q1 2026: 61 shipments, 4 suppliers, Spain-dominant sourcing.
XIROMED executed 61 shipments in Q1 2026 across 4 suppliers in 2 countries. Spain dominated sourcing at 78.7% of volume, led by CHEMO IBERICA with 48 shipments. India provided the secondary source at 16.4% of shipments, split among three Senador Laboratories entities. The import portfolio concentrated on HS Chapter 30 (pharmaceutical products).
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
XIROMED recorded no sanctions watchlist matches and no suppliers with Uyghur Forced Labor Prevention Act (UFLPA) exposure in Q1 2026. The importer's overall supplier-risk score is 78 (grade B).
4 distinct tier-1 suppliers in Q1 2026
| CHEMO IBERICA | Spain | 48 |
| SENADOR LABORATORIES PRIVATE | India | 5 |
| SENADOR LABORATORIES | India | 4 |
| SENADOR LABORATORIES PRIVATE LIMITE | India | 1 |
Share of Q1 2026 inbound shipments by source country
3 tier-2 + 1 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.